|
Details of activity:
|
Active against non-tuberculous mycobacteria: Mycobacterium abscessus, Mycobacterium avium, Mycobacterium chimaera , Mycobacterium intracellulare; nitric oxide is a cell-membrane active agent (lipid peroxidation), additionally induces oxidative and nitrosative stress (by reactive nitrogen species)
|
|
Propensity to select resistant mutants:
|
No
|
|
Description:
|
Synthetic compound; provides a sustained release of nitric oxide at physiological conditions; 2.5-3.1 CFU/ml log reduction in Mycobacterium abscessus infection in macrophages
|
|
Institute where first reported:
|
Vast Therapeutics, Durham, North Carolina, USA
|
|
Year first mentioned:
|
2024
|
|
Development status:
|
Experimental
|